Saturday 17 October 2026
Export LFST’s income statement to Excel — free account
LifeStance Health Group, Inc.
LFST Healthcare Medical Care Facilities
LifeStance Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 13.9% from fiscal 2024. In the quarter to June 2026, revenue grew 26.1%, EPS grew 700.0%, free cash flow grew 55.2% and total debt fell 5.08%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
11.74
0.63
−5.09%
Follow LFST
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 283.87 | 101.11 | 80.53 |
P/S ratio |
1.56 | 1.91 | 1.65 | 2.59 | |
P/FCF ratio |
17.83 | 24.70 | 17.30 | 23.62 | |
P/Operating CF |
78.00 | 47.21 | 74.51 | 41.11 | |
P/B ratio |
1.43 | 1.79 | 1.67 | 2.78 | |
Price to Tangible BV |
114.17 | 54.35 | 467.56 | 0.00 | |
EV/Sales |
1.60 | 1.92 | 1.70 | 2.61 | |
EV/EBITDA |
34.13 | 34.22 | 25.30 | 30.90 | |
EV/Operating CF |
14.54 | 18.71 | 13.90 | 19.00 | |
EV/FCF |
18.37 | 24.86 | 17.77 | 23.81 | |
Quick Ratio |
1.42 | 1.37 | 1.33 | 1.23 | |
Current Ratio |
1.58 | 1.65 | 1.48 | 1.38 | |
Net Debt/EBITDA |
3.09 | 0.54 | 1.89 | 0.73 | |
Debt/Assets |
12.54% | 12.07% | 12.23% | 11.87% | |
Debt/Equity |
0.18 | 0.17 | 0.18 | 0.18 | |
Asset Turnover |
0.64 | 0.66 | 0.70 | 0.73 | |
Operating CF/Net income |
25.34 | 4.93 | 2.32 | 4.23 | |
Capex/Depreciation |
(0.74) | (0.80) | (0.79) | (0.83) | |
Interest Coverage |
2.63 | 6.29 | 12.43 | 11.65 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
26.28% | 24.80% | 24.87% | 24.84% | |
Intangible Assets out of Total Assets |
0.69 | 0.67 | 0.69 | 0.68 | |
Share Based Compensation of Revenue |
5.03% | 4.37% | 3.77% | 4.54% | |
Graham Net Nets |
(0.14) | (0.10) | (0.13) | (0.08) | |
Graham Number |
0.00 | 1.48 | 2.33 | 3.40 | |
Earnings Yield |
(0.46%) | 0.35% | 0.99% | 1.24% | |
Free Cash Flow Yield |
5.61% | 4.05% | 5.78% | 4.23% | |
Revenue per Share |
0.94 | 0.99 | 1.04 | 1.14 | |
Operating CF per Share |
0.07 | 0.15 | 0.09 | 0.26 | |
Capex per Share |
(0.03) | (0.03) | (0.03) | (0.03) | |
Free Cash Flow per Share |
0.04 | 0.12 | 0.06 | 0.23 | |
Cash per Share |
0.53 | 0.64 | 0.50 | 0.59 | |
Shareholders Equity per Share |
3.86 | 3.94 | 3.82 | 3.85 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.86 | 3.94 | 3.82 | 3.85 | |
Free Cash Flow |
17.00 | 46.65 | 22.34 | 87.92 | |
Working Capital |
131.82 | 164.24 | 116.18 | 103.21 | |
Capital Expenditures |
(10.29) | (10.91) | (10.77) | (11.99) | |
Net Current Asset Value |
(295.85) | (266.72) | (312.55) | (326.38) | |
EV/EBIT |
307.99 | 113.25 | 56.54 | 52.79 | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 | |
Price to Operating Income |
298.79 | 112.54 | 55.03 | 52.37 | |
| Other line items | |||||
Average Receivables |
139.62 | 113.76 | 131.64 | 120.22 | |
Average Payables |
9.75 | 6.68 | 5.85 | 9.42 | |
Average Assets |
2,128.46 | 2,161.12 | 2,125.28 | 2,164.15 | |
Average Common Equity |
1,464.92 | 1,483.65 | 1,467.26 | 1,475.53 |
Columns are period end dates